News & Events

Cost Advantage of Sotorasib in KRAS G12C–Mutated NSCLC

Cost Advantage of Sotorasib in KRAS G12C–Mutated NSCLC

Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape

Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape

Stage Ⅳb Pulmonary Sarcomatoid Carcinoma with EGFR L861Q KRAS Co-mutation and High PD-L1 Expression Neoadjuvant Immunochemotherapy Combined with Surgery Achieves Near MPR

Stage Ⅳb Pulmonary Sarcomatoid Carcinoma with EGFR L861Q KRAS Co-mutation and High PD-L1 Expression Neoadjuvant Immunochemotherapy Combined with Surgery Achieves Near MPR

Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond

Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond

Optimized lipid nanoparticles for pulmonary delivery of CRISPR/Cas9 targeting KRAS G12S in lung cancer

Optimized lipid nanoparticles for pulmonary delivery of CRISPR/Cas9 targeting KRAS G12S in lung cancer